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Abstract: Silver has been used as an antimicrobial agent for a long time in different forms, but 
silver nanoparticles (nanosilver) have recently been recognized as potent antimicrobial agents. 
Although nanosilver is finding diverse medical applications such as silver-based dressings 
and silver-coated medical devices, its dermal and systemic toxicity via dermal use has not yet 
been identified. In this study, we analyzed the potential toxicity of colloidal nanosilver in acute 
and subchronic guinea pigs. Before toxicity assessments, the size of colloidal nanosilver was 
recorded in sizes ,100 nm by X-ray diffraction and transmission electron microscopy. For 
toxicological assessments, male guinea pigs weighing 350 to 400 g were exposed to two different 
concentrations of nanosilver (1000 and 10,000 µg/mL) in an acute study and three concentrations 
of nanosilver (100, 1000, and 10,000 µg/mL) in a subchronic study. Toxic responses were 
assessed by clinical and histopathologic parameters. In all experimental animals the sites of 
exposure were scored for any type of dermal toxicity and compared with negative control 
and positive control groups. In autopsy studies during the acute test, no significant changes in 
organ weight or major macroscopic changes were detected, but dose-dependent histopathologic 
abnormalities were seen in skin, liver, and spleen of all test groups. In addition, experimental 
animals subjected to subchronic tests showed greater tissue abnormalities than the subjects of 
acute tests. It seems that colloidal nanosilver has the potential to provide target organ toxicities 
in a dose- and time-dependent manner.
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Introduction
The increase in the applications of manufactured nanoparticles, which are composed 
mostly of metal and metal oxides, is increasing the potential for exposure among 
manufacturers and consumers.1 The major toxicological concern associated with 
manufactured nanomaterials is that some of are redox active, and some particles are 
transported across cell membranes and interact with subcellular organelles.2 Thus, 
evaluation of their toxicity on acute and subchronic exposure is essential.
The medical use of silver dates back centuries. Many of the industrial silver 
compounds, including nitrate, chloride, bromide, acetate, oxide, sulfate, and cyanide,3 
can be released in to the environment from various sources.4 Silver can be found in 
low levels in many tissues,4–7 but without any clear physiologic function. Dermal 
exposure to high doses of silver causes argyria and mild allergic responses.8 but the 
toxicity profile of dermal exposure to nanosilver with acute and subchronic treatment 
has not yet been identified.
Silver has been used as an antimicrobial agent for a long time in the form of 
metallic silver and silver sulfadiazine ointments.9 However, it has recently been International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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reported that nanosilver in the form of colloidal silver has 
been used for more than 100 years and has been registered as 
a biocidal material in the United States since 1954.10 Silver 
nanoparticles have recently been recognized as antimicrobial 
agents and are finding diverse medical applications such as 
silver-based dressings and, silver-coated medical devices.11,12 
This nanoparticle can damage bacterial cell walls and cause 
cell death.13 Although nanosilver magnifies the therapeutic 
effects of silver, its safety profile has remained controversial 
compared with silver compounds. Because of the importance 
of dermal exposure to nanosilver in different health products 
we compared the dermal toxicity of nanosilver and silver 
nitrate (AgNO3) in the guinea pig by acute and subchronic 
tests.
Materials and methods
silver nanoparticles
Silver nanoparticles were purchased from QuantumSphere 
Inc., (Santa Ana, CA). Three different aqueous solutions 
(100, 1000, and 10,000 µg/mL) were provided by Dr K Gilani 
in the Pharmaceutics Lab., Faculty of Pharmacy, Tehran 
University of Medical Sciences.
experimental animals and housing 
conditions
Forty-eight experimental male Hartley albino guinea pigs were 
obtained from the Pasteur Institute of Iran at five to six weeks of 
age and 350 to 450 g body weight. All guinea pigs were housed 
in stainless steel cages and allowed to adapt to the conditions 
of the animal house for 14 days before the experiments. The 
animals were maintained on a 12 hour dark/light cycle at about 
22 ± 3°C and allowed free access to a standard laboratory diet, 
vitamin C, and tap water ad   libitum during the experiments. The 
48 animals were randomly divided to eight treatment groups 
of six animals each. Three groups were allocated to an acute 
dermal toxicity assessment and the other five to a subchronic 
dermal toxicity assessment. All animal studies were conducted 
according to the US National Institute of Health (NIH publica-
tion no. 85-23, revised 1985) guidelines.
Transmission electron microscopy  
and X-ray diffraction tests
The extent and size of silver nanoparticles were determined 
by transmission electron microscopy (TEM) and X-ray 
diffraction (XRD) using standard equipment (Siemens 
with Cu source, 40 kV and 30 mA). Sample patterns were 
determined at 5 to 75 degrees (2ϑ).14
Acute dermal toxicity studies
The acute dermal toxicity test was performed in compliance 
with the OECD guideline o402. After performing a toxicity 
test at up to 10,000 µg/mL on three animals, six male animals 
per group were used for the acute test. This preliminary study 
estimated the dermal LD50 of this substance and served a 
basis for classification and labeling of dermal nanosilver. 
It was the initial step for establishing the dosage regimen in 
the subchronic toxicity test. The Draize test was used also 
initially to assess primary skin irritation potential of the test 
material.15
The test substance at 100 and 1000 µg/mL and 100 µg/mL 
of a solution of AgNO3 were applied to 10% of the body 
surface area of experimental animals and positive control 
animals, respectively. Untreated portions of the body 
surface area of all animals served as negative controls. 
The shaved and rubbed areas were covered with sterile 
gas and fixed with cloth glue. Animals were put inside a 
restrainer for a period of four to five hours and the skin 
of each animal was studied in intervals of 1, 24, 48, and 
72 hours for presence of any edema, erythema, or any type 
of dermal change.
Observations continued for 14 days. During the first day 
the animals were observed frequently and then observations 
were made daily. Necropsy of all animals was carried out 
and all gross pathologic changes were studied.
subchronic dermal toxicity studies
Thirty guinea pigs were randomly divided into five groups 
(six males per group) and an area 5 cm × 5 cm of the back 
zone of each animal was shaved for treatment. Continuous 
back shaving was performed two to three times per week 
during the rest of study (13 weeks).
The shaved skin of experimental animals was rubbed 
five times per week with the test material at 100, 1000, and 
10000 µg/mL and skin of positive controls was rubbed with 
100 µg/mL of AgNO3 solution; the other parts of body in 
all treatment groups were kept untreated as negative control. 
Dermal application was performed once daily for five days 
per week over a period of 13 weeks.
clinical examinations
Clinical signs were observed and weights were recorded 
once daily in the acute study and two times per week in the 
subchronic study. The recording items were divided into 
three categories: cageside observations, and neurologic and 
physical examinations.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Results
TeM studies
Nanosilver particles were detected in sizes of ,100 nm 
(Figure 1).
XrD examination
Nanosilver particles were observed in the ranges of 38, 44, 
64/5 degrees (2ϑ) (Figure 2).
Mortality
Because no mortality was recorded during dermal application 
of different concentrations of nanosilver at doses of up to 
10,000 µg/mL in the preliminary study, we considered it to 
be a nontoxic agent in acute dermal exposure.
Acute dermal toxicity studies
No abnormal change was detected in the negative control 
(Figure 3A). In the AgNO3 group, a reduced thickness of 
epidermis and increased regular collagen fiber in papillary 
layer were observed. In addition, mononuclear inflammation 
was noted in this group of animals (Figure 3B).
Although a reduced thickness of epidermis and reduced 
thickness of papillary layer were seen in the low-dose 
nanosilver group (100 µg/mL), collagen fibers were regular 
(Figure 3C). Higher levels of histopathologic changes were 
detected in the high-dose group (Figure 3D). It seems that 
increased concentrations of nanosilver increased the toxic 
Figure 1 TeM image showing nanosilver particles of sizes ,100 nm.
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Figure 2 Nanosilver particles by XrD were observed in the ranges of 38, 44, 64/5 degrees (2θ).
Pathologic studies
Tissue was removed from skin, liver, and spleen of three 
animals per group for histopathologic studies. The tissues 
were fixed in 10% buffered formalin and dehydrated in a 
graded series of alcohol, cleared in xylene, and embedded 
in paraffin wax. Multiple sections from each block were 
prepared at 5 µm and stained with hematoxylin and eosin 
(H&E) for histopathologic studies.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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responses of skin. Details of histopathologic abnormalities 
in the acute study are shown in Table 1.
subchronic toxicity test
skin
Similar skin inflammatory responses were recorded in all 
treatment groups in the subchronic study. No abnormal 
change was detected in the negative control (Figure 4A). 
In the AgNO3 group, a reduced thickness of the epidermis 
and papillary layer were seen. Moreover the decreased 
thickness of dermis and epidermis increased the numbers of 
Langerhans cells. Figure 4B shows inflammation, decreased 
thickness of the papillary layer, and increased collagen levels 
of the dermis layer.
In animals treated with 100 µg/mL nanosilver, decreased 
thickness of epidermis and dermis were detected, as were 
increased levels of Langerhans cells, inflammation, and 
decreased papillary layer with regular collagens fibers 
(Figure 4C).
In animals treated with a 1000 µg/mL of nanosilver, 
a reduced thickness of epidermis and dermis were seen, 
too. Increased levels of Langerhans cells and round cells, 
decreased papillary layer with regular collagen fibers and 
inflammation, and acidophilic cytoplasm in muscle fibers 
with inflammation were observed in endomysium. In addition 
some muscle fibers were surrounded by macrophages 
(Figure 4D).
In the animals treated with 10,000 µg/mL nanosilver, 
muscle fibers with acidophilic cytoplasm were surrounded 
by macrophages. In addition to degenerative fibers, increased 
levels of macrophage in endomysium were observed with 
inflammation. All observed toxic skin responses were 
dose- and time-dependent, which means that greatest 
histopathologic changes were seen in the 10,000 µg/mL group 
in the 13-week study and the lowest in the 100 µg/mL group 
in the acute test (Figure 4E). All details of histopathologic 
changes in the subchronic test are listed in Table 2A.
Liver
In the AgNO3 and nanosilver groups, destruction of 
hepatocyte cords was seen but in the test groups this pattern 
was magnified by increased nanosilver concentrations. 
Moreover, overproduction of Kupffer cells and degeneration of 
hepatocytes were seen and increased with increasing nanosilver 
concentrations in the test groups (Figures 6B–E). Necrosis 
was observed only at the highest nanosilver concentration 
(10,000 µg/mL). Observed histopathologic changes clearly 
showed necrosis at the maximum nanosilver concentration. 
Thus, the results suggest a dose-dependent hepatotoxic effect of 
nanosilver by dermal exposure. More details on histopathologic 
changes of the liver are listed in Table 2C.
spleen
Red capsules and white pulp were seen regularly in the 
spleens of the control group without any abnormal change 
or inflammation (Figure 5A). Red capsules were thinner 
in the AgNO3 group with inflammation and white pulp 
hypertrophy (Figure 5B). In the low-dose (100 µg/mL) group, 
red capsules were much thinner, with signs of inflammation,   
accumulation of red blood cells, and white pulp atrophy 
Table 1 Dermal histopathologic changes in acute study
Group Inflammation  Round cell Clear cell Reduced epidermis Reduced papillary
control  - - - - -
AgNO3 +* + - + -
Nanosilver 100 μg/mL + + + + +
Nanosilver 10,000 μg/mL + ++** ++ ++ ++
A
Epidermis
Dermis 
B
Epidermis 
Dermis
Irregular collagen fiber 
C
Epidermis
Dermis
Derm
D
Langerhans cell 
Plasma cell
Figure 3 h&e stained skin sections in an acute toxicity study (× 40). A) Negative 
control; B) AgNO3 group: reduced thickness of epidermis and increased regular 
collagen fiber in papillary layer and mononuclear inflammation; C) Low-dose nanosilver 
group with reduced thickness of epidermis, reduced thickness of papillary layer, and 
regular collagen fibers; D) high-dose nanosilver group with reduced thickness of 
epidermis, reduced thickness of papillary layer, and irregular collagen fibers.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(Figure 5C). In the medium-dose (1000 µg/mL) group the 
same pattern was repeated (Figure 5D). The highest levels 
of red pulp inflammation, white pulp atrophy, and thinnest 
capsules were seen in the high-dose group, but white pulp 
hypertrophy was a specific response to AgNO3, not to any 
nanosilver dose (Figure 5B). More details on histopathologic 
changes of the spleens are shown in Table 2C.
Discussion
Nanosilver has become one of the most widely used nano-
materials in consumer products because of its antimicrobial 
and antiseptic properties. Because of public concern over 
the potential adverse effects of nanosilver,16 we assessed the 
toxicity potentials of different concentrations of nanosilver 
by dermal application because our knowledge of toxicology 
has been derived only from studies on administration of nano-
silver inhalational1 or by mouth.17 In these previous studies, 
animals exposed to nanosilver showed minimal pulmonary 
inflammation or cytotoxicity following subacute exposures 
but longer-term exposures with higher body burdens of 
nanosilver are needed to ensure that there are no chronic 
effects and to evaluate possible translocation of nanosilver 
to other organs.
The present study clearly showed that dermal contact 
with nanosilver may cause histopathologic abnormalities 
of the skin, liver, and spleen of animals, which could be 
magnified by increased concentrations over longer-term 
exposures. The present study has emphasized also that sub-
chronically treated animals exhibit higher dermal, hepatic, 
and immunological toxicity signs compared with acutely 
treated animals.
One of the classical toxic responses to the silver is 
argyria, which was reported for the first time by Blumberg 
and Carey in a woman who had ingested a total dose of 6.4 g 
silver nitrate over a 1-year period of time and showed argyria 
symptoms after the first six months of exposure.18 Rosenman 
et al reported also respiratory irritation, abdominal pain, and 
decreased night vision in workers exposed to AgNO3 and 
silver oxide dusts over one to ten years.4 They later showed 
that occupational exposure to silver compounds in a group 
of workers may cause respiratory irritation, decreased night 
vision, abnormal rise in N-acetyl-B-D glucoseaminidase, 
and decreased creatinine clearance.19 Discoloration of the 
conjunctiva and cornea in some workers was reported after 
inhalational exposure.20 Williams et al, in a case study of 
a 51-year-old man exposed to silver compounds, showed 
corneal and conjunctival argyrosis.21 Chang et al recorded 
a case study of a 59-year-old man who was distressed from 
dermal and face color change. He had ingested colloidal 
silver two to three times per year for two years and showed 
endocrine disruptions such as hyperlipidemia, hypertension, 
and diabetes as well as blue-grey facial signs.22 Neurologic 
symptoms are an unusual consequence of silver toxicity which 
B
AC
D
E
Figure 4 h&e stained skin sections in subchronic toxicity (× 40). A) Normal skin 
in control group; B) AgNO3 group with reduced thickness of dermis and epidermis, 
increased Langerhans cells, inflammation, decreased thickness of papillary zone layer, 
and increased collagen levels of dermis layer; C) skin abnormalities in low-dose 
nanosilver group; D) skin abnormalities in high-dose nanosilver group; E) highest 
level of dermal toxicity (see text for further details).
Table 2A Dermal histopathologic changes in subchronic test
Group Inflammation  Round cell Clear cell Decreased 
epidermis
Decreases 
collagen fiber
Decreased lamina 
propria attachments
control - - - - - -
AgNO3 + - + + + -
Nanosilver 100 μg/mL + - + + + -
Nanosilver 1000 μg/mL + + + + ++ -
Nanosilver 10,000 μg/mL + ++ ++ ++ +++ ++
Notes: severe (+++); moderate (++); mild (+); none (-).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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was recently reported in a 75-year-old man who had a history 
of self-medication with colloidal silver and presented with 
myoclonic seizures.23
Our study clearly showed that the toxic effects of nanosilver 
depend on the route of administration. Moreover dose- and 
time-dependent toxic effects of nanosilver via dermal application 
in skin, liver, and spleen of male guina pigs were completely 
different from what has been seen after clinical poisoning with 
silver salts via inhalational or oral routes of administration.
Some reports have proved that many medical devices 
loaded with silver could release silver ions (Ag+) which could 
be translocated through the blood circulation and accumulate 
in some organs such as the liver and kidney. It may induce 
hepatotoxicity or renal toxicity and may lead to death in 
some cases of extreme exposure to a certain dose of Ag+.24 
We have shown that silver nanoparticles with properties 
similar to those of Ag+ could be translocated in the body 
and cause histopathologic changes in the liver and spleen 
unlike those caused by AgNO3 given by the same route of 
administration. For example, mononuclear inflammation 
was noted for AgNO3-treated animals only, whereas reduced 
epidermal thickness and thickness of papillary layer were 
seen after administration of different concentrations of 
nanosilver in our acute study.
Braydich-Stoll et al25 reported potential cytotoxicity of nano-
silver in vitro. They used nanosilver in different concentrations 
on mammalian stem cells and showed apoptosis and necrosis 
in cells exposed to $10 µg/mL nanosilver. Mitochondrial 
function and cell viability were reduced by silver   nanoparticles 
at concentrations of 1 to 5 µg/mL.25 We used doses of 10,000, 
1000, and 100 µg/mL solutions without recording any sign of 
mortality. Although the   concentrations of nanosilver were high 
and unrealistic, to our knowledge this is the first study on dermal 
and systemic toxicity of nanosilver in acute and subchronic 
treatment. It is necessary to conduct the same study with lower 
doses and find the NOAEL (no observable adverse effect level) 
of nanosilver by dermal application.
Conclusion
The target organs for silver nanoparticles were found to be 
the skin, liver, and spleen in the male guinea pig after dermal 
application. Although a NOAEL of 30 mg/kg and LOAEL 
(lowest observable adverse effect level) of 125 mg/kg17 were 
suggested for oral administration of silver nanoparticles 
in the rat, at doses of 0.1 mg/kg (100 µg) was not a safe 
dose for dermal application. Although no sign of mortality 
was detected in any of the treatment groups, significant 
dose-dependent histopathologic changes were found in all 
treatment groups compared with controls. The present results 
indicate that exposure to .0.1 mg/kg of silver nanoparticles 
may result in slight liver, spleen, and skin damage. It could 
be concluded from this study that the toxicity profile of 
nanosilver differs from that of silver even when given by the 
same route of administration. The results suggest that it is 
necessary to determine the association between the period of 
exposure and histopathologic changes with lower doses over 
Table 2C histopathologic changes of the spleen in subchronic test
Group Inflammation Kupffer cell Limited pale 
destruction
Hepatic cord 
destruction
Necrosis Hepatocyte 
degeneration 
control  - - - - - -
AgNO3 + ++ ++ ++ - ++
Nanosilver 100 μg/mL + + + + - +
Nanosilver 1000 μg/mL ++ ++ ++ ++ - ++
Nanosilver 10,000 μg/mL ++ +++ +++ +++ + +++
Notes: severe (+++); moderate (++); mild (+); none (-).
Table 2B Liver histopathologic changes in subchronic test
Group Inflammation Thin capsule White pulp atrophy  Red pulp 
inflammation
White pulp 
hypertrophy
control - - - - -
AgNO3 + + - + +
Nanosilver 100 μg/mL + + + + -
Nanosilver 1000 μg/mL + + + + -
Nanosilver 10,000 μg/mL + ++ ++ ++ -
Notes: severe (+++); Moderate (++); mild (+); none (-).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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different time periods. The effect of particle shape and size 
on the toxicity profile of nanosilver administered by different 
routes should be determined in future studies.
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